[go: up one dir, main page]

LT2696848T - Liofilizuotos vaisto nanosuspensijos - Google Patents

Liofilizuotos vaisto nanosuspensijos

Info

Publication number
LT2696848T
LT2696848T LTEP12713187.8T LT12713187T LT2696848T LT 2696848 T LT2696848 T LT 2696848T LT 12713187 T LT12713187 T LT 12713187T LT 2696848 T LT2696848 T LT 2696848T
Authority
LT
Lithuania
Prior art keywords
freeze dried
dried drug
drug nanosuspensions
nanosuspensions
freeze
Prior art date
Application number
LTEP12713187.8T
Other languages
English (en)
Inventor
Sabine Karine Katrien Inghelbrecht
Henning GIESELER
Jakob Andreas BEIROWSKI
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of LT2696848T publication Critical patent/LT2696848T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP12713187.8T 2011-04-15 2012-04-13 Liofilizuotos vaisto nanosuspensijos LT2696848T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161475811P 2011-04-15 2011-04-15
PCT/EP2012/056818 WO2012140220A1 (en) 2011-04-15 2012-04-13 Freeze dried drug nanosuspensions

Publications (1)

Publication Number Publication Date
LT2696848T true LT2696848T (lt) 2020-09-10

Family

ID=45937395

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP12713187.8T LT2696848T (lt) 2011-04-15 2012-04-13 Liofilizuotos vaisto nanosuspensijos

Country Status (22)

Country Link
US (5) US20140038996A1 (lt)
EP (3) EP2696848B1 (lt)
JP (1) JP6161593B2 (lt)
CN (2) CN108210469A (lt)
AU (1) AU2012241726C1 (lt)
BR (1) BR112013026363B1 (lt)
CA (1) CA2832410C (lt)
CY (1) CY1123434T1 (lt)
DK (1) DK2696848T3 (lt)
ES (2) ES3037398T3 (lt)
HK (1) HK1257447A1 (lt)
HR (1) HRP20201241T1 (lt)
HU (1) HUE050970T2 (lt)
LT (1) LT2696848T (lt)
MX (1) MX362344B (lt)
PL (1) PL2696848T3 (lt)
PT (1) PT2696848T (lt)
RS (1) RS60651B1 (lt)
RU (1) RU2643062C2 (lt)
SI (1) SI2696848T1 (lt)
SM (1) SMT202000504T1 (lt)
WO (1) WO2012140220A1 (lt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012247545B2 (en) * 2011-04-28 2016-08-11 Oncopeptides Innovation Ab Lyophilized preparation of cytotoxic dipeptides
CN108685860B (zh) 2012-10-26 2022-04-05 肿瘤多肽股份公司 美法仑氟灭酰胺的冻干制剂
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
SG11201507681PA (en) * 2013-03-15 2015-10-29 Iceutica Inc Abiraterone acetate formulation
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
HUP1500055A1 (hu) * 2015-02-09 2016-08-29 Druggability Technologies Ip Holdco Ltd Abirateron acetát komplexei, eljárás elõállításukra, és az azokat tartalmazó gyógyászati készítmények
CN105902496B (zh) * 2016-04-18 2019-10-25 沈阳药科大学 一种纳米混悬液固体化过程的处理方法
US10507165B2 (en) * 2017-05-31 2019-12-17 Adienne Pharma & Biotech Sa Multi chamber flexible bag and methods of using same
RU2665383C9 (ru) * 2017-06-22 2019-07-23 Общество с ограниченной ответственностью "Вириом" Фармацевтическая наносуспензия для терапии ВИЧ-инфекции
AU2018298855B2 (en) 2017-07-14 2024-07-18 Janssen Pharmaceutica Nv Long-acting formulations
RU2721562C1 (ru) * 2019-06-04 2020-05-20 Автономная некоммерческая образовательная организация высшего образования "Сколковский институт науки и технологий" Способ загрузки неорганических наночастиц или органических молекул в пористые частицы микронного или субмикронного размера
CN111149795A (zh) * 2020-01-14 2020-05-15 成都艾伟孚生物科技有限公司 一种冷冻保护剂及其应用和一种精子冷冻液及其制备方法
CN113440529B (zh) * 2020-03-25 2023-11-14 江苏恒瑞医药股份有限公司 一种可注射的药物组合物及其制备方法
WO2021222545A1 (en) * 2020-04-29 2021-11-04 The Texas A&M University System Naloxone nanoparticle compositions and methods thereof
MX2023000439A (es) 2020-07-09 2023-02-09 Janssen Pharmaceutica Nv Formulaciones a largo plazo.
JP2023532981A (ja) 2020-07-09 2023-08-01 ヤンセン ファーマシューティカ エヌ.ベー. 長時間作用型配合物
JP2023532982A (ja) 2020-07-09 2023-08-01 ヤンセン ファーマシューティカ エヌ.ベー. 長時間作用型配合物
WO2022079739A1 (en) 2020-10-14 2022-04-21 Cipla Limited Fixed dose compositions of cabotegravir and rilpivirine
JP6886551B1 (ja) * 2020-11-06 2021-06-16 医療法人祥和会 歯科用の局所麻酔液
KR20230110763A (ko) * 2020-11-17 2023-07-25 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 질환 또는 장애의 치료 또는 예방
CN112641950B (zh) * 2021-01-12 2022-12-16 北京德立福瑞医药科技有限公司 含有难溶性抗肿瘤活性剂的药物组合物及其制备方法
US20250049709A1 (en) * 2021-12-11 2025-02-13 Beloteca, Inc. Ziprasidone formulations
WO2023154454A1 (en) * 2022-02-10 2023-08-17 Soligenix, Inc. Telmisartan nanosuspension for therapy of respiratory infections and methods of making and using same
CN119403545A (zh) * 2022-04-22 2025-02-07 爱尔兰詹森科学公司 冷冻干燥的组合物
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
CA3268292A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv LONG-ACTING FORMULAS
CN116115621A (zh) * 2022-10-31 2023-05-16 广州鹏兴医药科技有限公司 氢氯噻嗪组合物及其制备方法及氢氯噻嗪微针透皮贴剂
CN116421564B (zh) * 2023-03-09 2024-11-12 云南中医药大学 一种灯盏花素纳米粒及其制备方法
CN116919898B (zh) * 2023-09-15 2023-12-19 北京星辉再生科技有限责任公司 米诺地尔纳晶混悬液组合物、米诺地尔纳晶混悬液及其制备方法和应用
WO2025056094A1 (zh) * 2023-09-15 2025-03-20 广州帝奇医药技术有限公司 一种冻干制剂和注射液及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
FR2740686B1 (fr) 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
US20050004049A1 (en) 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
RU2331424C2 (ru) * 2002-12-13 2008-08-20 Джеготек Аг Топический состав, содержащий наночастицы спиронолактона
BR0215979A (pt) 2002-12-13 2005-11-01 Jagotec Ag Formulação de espironolactona nanoparticulada tópica, uso de nanossuspensões de espironolactona, sistema de rede cristalina, e, processo para a preparação de uma formulação de espironolactona nanoparticulada tópica
KR20070119678A (ko) * 2005-04-13 2007-12-20 화이자 프로덕츠 인코포레이티드 지속 방출되는 나노입자 조성물을 제공하기 위한주사가능한 저장소 제제 및 방법
EP1954252B1 (en) 2005-12-02 2016-02-03 GlaxoSmithKline Biologicals SA Nanoparticles for use in immunogenic compositions
AR061620A1 (es) * 2006-06-23 2008-09-10 Tibotec Pharm Ltd Suspensiones acuosas de tmc278
WO2008013416A1 (en) * 2006-07-27 2008-01-31 Amorepacific Corporation Process for preparing powder comprising nanoparticles of sparingly soluble drug
TWI494133B (zh) * 2007-03-14 2015-08-01 Tibotec Pharm Ltd 重組用粉末
HRP20131128T1 (hr) * 2007-07-12 2013-12-20 Janssen R&D Ireland Kristalni oblik (e) 4-[[4-[[4-(2-cijanoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrila
US8161810B2 (en) 2008-01-29 2012-04-24 Carefusion 303, Inc. Syringe imaging systems
CN101283982B (zh) * 2008-06-03 2010-06-02 南京工业大学 非诺贝特纳米混悬剂及其制备方法
CN101904820A (zh) * 2009-06-02 2010-12-08 姜玲敏 槲皮素纳米混悬剂冻干组合物及其制备方法和应用
CN101612131B (zh) * 2009-07-17 2011-09-14 郑州大学 2-甲氧基雌二醇纳米混悬剂冻干粉及其制备方法
CN101953808B (zh) * 2010-10-13 2013-03-13 厦门大学 抗肿瘤化合物去乙酰真菌环氧乙酯注射剂及其制备方法

Also Published As

Publication number Publication date
EP3799860B1 (en) 2025-06-25
WO2012140220A1 (en) 2012-10-18
CA2832410C (en) 2019-07-23
EP3799860C0 (en) 2025-06-25
US20220409616A1 (en) 2022-12-29
ES3037398T3 (en) 2025-10-01
EP4663243A2 (en) 2025-12-17
AU2012241726B2 (en) 2017-04-27
SMT202000504T1 (it) 2020-11-10
JP6161593B2 (ja) 2017-07-12
CN103764117A (zh) 2014-04-30
PT2696848T (pt) 2020-09-03
CA2832410A1 (en) 2012-10-18
SI2696848T1 (sl) 2020-10-30
US11819502B2 (en) 2023-11-21
MX362344B (es) 2019-01-11
DK2696848T3 (da) 2020-10-12
EP2696848A1 (en) 2014-02-19
RS60651B1 (sr) 2020-09-30
US20160317534A1 (en) 2016-11-03
BR112013026363A2 (pt) 2016-12-27
HRP20201241T1 (hr) 2020-11-27
HUE050970T2 (hu) 2021-01-28
PL2696848T3 (pl) 2020-12-28
US20190076428A1 (en) 2019-03-14
RU2643062C2 (ru) 2018-01-30
CY1123434T1 (el) 2021-12-31
EP2696848B1 (en) 2020-07-22
JP2014515021A (ja) 2014-06-26
US20140038996A1 (en) 2014-02-06
US10166231B2 (en) 2019-01-01
RU2013150803A (ru) 2015-05-20
US20240148726A1 (en) 2024-05-09
EP3799860A1 (en) 2021-04-07
CN108210469A (zh) 2018-06-29
US11389448B2 (en) 2022-07-19
AU2012241726A1 (en) 2013-10-24
MX2013011985A (es) 2013-11-04
HK1257447A1 (zh) 2019-10-18
AU2012241726C1 (en) 2017-09-14
BR112013026363B1 (pt) 2021-10-13
ES2823805T3 (es) 2021-05-10

Similar Documents

Publication Publication Date Title
PL2696848T3 (pl) Liofilizowane nanozawiesiny leków
PL2776416T3 (pl) Związki farmaceutyczne
GB201008005D0 (en) Pharmaceutical compounds
SG10201604667YA (en) Pharmaceutical preparation
GB201119799D0 (en) Pharmaceutical compounds
ZA201403832B (en) Pharmaceutical compounds
GB201105298D0 (en) Pharmaceutical preparation
GB201020161D0 (en) Pharmaceutical compounds
GB201118876D0 (en) Pharmaceutical compounds
SI2768485T1 (sl) Farmacevtska nanosuspenzija
GB201113163D0 (en) Pharmaceutical compounds
AU343043S (en) Herb chopper
PL2691119T3 (pl) Preparat farmaceutyczny
PL2394638T3 (pl) Nowe połączenia farmaceutyczne
HRP20141173T1 (hr) Medikament koji sadrži miramistin
GB201119796D0 (en) Pharmaceutical comopounds
GB201119942D0 (en) Better freeze drying device
ZA201301851B (en) Pharmaceutical combinations
GB201119941D0 (en) Improved freeze drying device
GB201118874D0 (en) Pharmaceutical compounds
GB201117359D0 (en) Pharmaceutical compounds
GB201118875D0 (en) Pharmaceutical compounds
GB201105026D0 (en) Pharmaceutical compounds
GB201101601D0 (en) Grain driers
GB201120735D0 (en) New pharmaceutical uses